November 25, 2016 - By Richard Conner
Interested investors have been looking for information on shares of MARINA BIOTECH CMN (OTCMKTS:MRNA) after the stock moved $-0.024, hitting the $0.0861 price point in a recent trade.
It’s the latest price, but let’s analyze how the stock has been doing recently. In the past year, MARINA BIOTECH CMN’s stock was -57.00%. According to the short interest report published recently, (MRNA) had 2,300 shorted shares for 0 days to cover. The prior short interest was 8,400 for a $-72.62 change. The 52-Week High and Low are noted here. -83.44% (High), 7.62%, (Low). The stock had 115,300 average volume.
Enroll for Our Newsletter Today and know if shares price of MARINA BIOTECH CMN (OTCMKTS:MRNA) is Ready to Breakout!
Penny stocks are often stated as risky investments that hardly pay off. Admittedly, there is fact to this, but with the right knowledge and tactics, it is possible to earn a significant amount of gain in penny stocks. Simply said, a penny stock is an equity that trades at a low price.
Irrespective of the name, penny stocks usually are priced over a penny, occupying a price range at or close to $1, though some are priced a fraction of a penny. Often referred to as micro-cap equities, the Securities & Exchange Commission classifies these types of securities as being $5 or less. Over-the-counter stocks are NOT listed on any of the formal exchanges.
So, penny stocks frequently fit in this segment, though many dodge this category. Over-the-counter (OTC) equities are stated to be risky as they aren’t contingent to the listing and reporting requirements of the reputed commodity exchanges.
Register in the Bar Below to Obtain Breaking Alerts on Shares That Are Set to Make a Move!
Penny shares can be listed on NASDAQ or other known stock exchanges, although many more cannot be found there. A major percentage of penny stocks are listed on the so-named ‘pink sheets’, i.e., daily news of OTC shares. They can even be seen on the ‘Over-the-Counter Bulletin Board.’ Commodities listed on the OTCBB fail to fulfill the listing guidelines of the NYSE or other known exchanges, although they are mandated to file financial statements with known regulators, such as the SEC. Penny shares are inexpensive, thus attractive to shareholders who lack the funds to buy comparatively expensive blue-chip stocks from large firms.
Penny stocks boast immense profit potential. Because these stocks trade cheap, even a slight jump in price turns to be profitable. Look out, however, because frequently shareholders may have trouble getting a decent amount of details about penny stocks. These kinds of shares tend to be latest in news, with almost no track record for investors research.
In addition, penny stocks show lack of market activity, with poor liquidity, making them difficult to sell. Poor liquidity results in penny stocks to be open to price influence.
A shady trader can simply buy large sums of shares, temporarily leading up the price, crafting artificial demand.
Disclaimer: Nothing mentioned in this publication is planned to constitute legal, securities, tax, or investment advice, nor a viewpoint regarding the relevance of any investment, nor any type of solicitation. The general information mentioned in this article should not be acted upon without getting specific tax, legal and investment advice from a certified professional.
More recent Marina Biotech, Inc. (OTCMKTS:MRNA) news were published by: Streetinsider.com which released: “Marina Biotech (MRNA) to Merge with IthenaPharma” on November 16, 2016. Also Marketwired.com published the news titled: “Marina Biotech to Present at the 9th Annual LD Micro Main Event” on November 25, 2016. Streetinsider.com‘s news article titled: “Marina Biotech (MRNA) Enters Agreement to Acquire Turing Pharma’s Intranasal …” with publication date: May 03, 2016 was also an interesting one.
Marina Biotech, Inc. is a biotechnology firm focused on the discovery, development and commercialization of nucleic acid therapies to treat orphan diseases. The company has a market cap of $10.09 million. The Company’s pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis , and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD). It has a 3.83 P/E ratio. It creates a range of therapeutics targeting coding and non-coding ribonucleic acid (RNA) through several mechanisms of action, such as RNA interference (RNAi), messenger RNA translational inhibition, exon skipping, microRNA (miRNA) replacement, miRNA inhibition and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.